Nile for Pharmaceuticals and Chemical Industries Past Earnings Performance
Past criteria checks 3/6
Nile for Pharmaceuticals and Chemical Industries has been growing earnings at an average annual rate of 39.6%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 18.8% per year. Nile for Pharmaceuticals and Chemical Industries's return on equity is 21.5%, and it has net margins of 10%.
Key information
39.6%
Earnings growth rate
39.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 9.8% |
| Revenue growth rate | 18.8% |
| Return on equity | 21.5% |
| Net Margin | 10.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Nile for Pharmaceuticals and Chemical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 936 | 94 | 98 | 0 |
| 30 Sep 22 | 901 | 92 | 94 | 0 |
| 30 Jun 22 | 877 | 90 | 92 | 0 |
| 31 Mar 22 | 812 | 73 | 87 | 0 |
| 31 Dec 21 | 788 | 67 | 84 | 0 |
| 30 Sep 21 | 744 | 61 | 80 | 0 |
| 30 Jun 21 | 756 | 64 | 83 | 0 |
| 31 Mar 21 | 762 | 87 | 76 | 0 |
| 31 Dec 20 | 785 | 98 | 80 | 0 |
| 30 Sep 20 | 818 | 100 | 92 | 0 |
| 30 Jun 20 | 813 | 93 | 95 | 0 |
| 31 Mar 20 | 807 | 63 | 99 | 0 |
| 31 Dec 19 | 758 | 47 | 98 | 0 |
| 30 Sep 19 | 713 | 32 | 91 | 0 |
| 30 Jun 19 | 638 | 7 | 83 | 0 |
| 31 Mar 19 | 606 | 0 | 85 | 0 |
| 31 Dec 18 | 548 | -25 | 81 | 0 |
| 30 Sep 18 | 475 | -33 | 77 | 0 |
| 30 Jun 18 | 460 | -18 | 79 | 0 |
| 31 Mar 18 | 430 | -4 | 78 | 0 |
| 31 Dec 17 | 419 | 10 | 80 | 0 |
| 30 Sep 17 | 433 | 22 | 81 | 0 |
| 30 Jun 17 | 418 | 23 | 78 | 0 |
| 31 Mar 17 | 417 | 24 | 76 | 0 |
| 31 Dec 16 | 383 | 20 | 72 | 0 |
| 30 Sep 16 | 351 | 13 | 68 | 0 |
| 30 Jun 16 | 330 | 9 | 65 | 0 |
| 31 Mar 16 | 313 | 14 | 60 | 0 |
| 31 Dec 15 | 298 | 15 | 61 | 0 |
| 30 Sep 15 | 290 | 18 | 60 | 0 |
| 30 Jun 15 | 287 | 18 | 60 | 0 |
| 31 Mar 15 | 291 | 14 | 62 | 0 |
| 31 Dec 14 | 306 | 16 | 62 | 0 |
| 30 Sep 14 | 323 | 17 | 63 | 0 |
| 30 Jun 14 | 336 | 17 | 64 | 0 |
| 31 Mar 14 | 349 | 16 | 67 | 0 |
| 31 Dec 13 | 359 | 20 | 66 | 0 |
| 30 Sep 13 | 355 | 19 | 65 | 0 |
| 30 Jun 13 | 354 | 22 | 64 | 0 |
Quality Earnings: NIPH has a high level of non-cash earnings.
Growing Profit Margin: NIPH's current net profit margins (10%) are higher than last year (8.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NIPH's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare NIPH's past year earnings growth to its 5-year average.
Earnings vs Industry: NIPH earnings growth over the past year (39.6%) exceeded the Pharmaceuticals industry 22.4%.
Return on Equity
High ROE: NIPH's Return on Equity (21.5%) is considered high.